Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0028 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 |
filingDate |
2016-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcdf2c9b0be6903d0c7d9f133b39dc09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de9691cbd608af946064231166e9fd60 |
publicationDate |
2016-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2016203771-A1 |
titleOfInvention |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
abstract |
The present invention is directed to methods for the treatment of treatment-refractory depression or treatment-resistant depression comprising administering to a patient in need thereof, a therapeutically effective amount of esketamine as mono-therapy or as combination therapy with at least on antidepressant. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108836967-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11173134-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10869844-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446260-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11311500-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11707440-B2 |
priorityDate |
2012-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |